<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02701816</url>
  </required_header>
  <id_info>
    <org_study_id>1-2015-0074</org_study_id>
    <nct_id>NCT02701816</nct_id>
  </id_info>
  <brief_title>Korean Multicenter Registry of INNOVA Stent for Femoropopliteal Artery Disease: (K-INNOVA Registry)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Prospective, single-arm, multi-center registry study

        -  A total of 150 subjects with femoropopliteal artery disease who meet all inclusion and
           exclusion criteria will be included.

        -  Patients will be followed clinically for 12 months after the procedure.

        -  Duplex ultrasound, CT or catheter-based angiography follow-up according to participating
           hospital's protocol will be performed at 12 months.

        -  Presence of stent fracture will be evaluated by plain radiography or fluoroscopy at 12
           months.

        -  Quality of life by standardized questionnaires (at baseline &amp; at 1 &amp; 12 months)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary patency rate</measure>
    <time_frame>12 months after the index procedure</time_frame>
    <description>Absence of restenosis &gt;50%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization rate</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent fracture rate</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Quality of life by standardized questionnaires</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Femoropopliteal Artery Disease</condition>
  <arm_group>
    <arm_group_label>K-INNOVA</arm_group_label>
    <description>Patients with femoropopliteal artery disease undergoing endovascular therapy using Innova stent (Boston Scientific).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>innova stent (Boston scientific)</intervention_name>
    <arm_group_label>K-INNOVA</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Femoropopliteal artery disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 19 years of older

          2. Symptomatic peripheral artery disease:

               -  Moderate or severe claudication (Rutherford category 2 or 3)

               -  Critical limb ischemia (Rutherford category 4-5)

          3. Femoropopliteal artery lesions with stenosis &gt; 50%

          4. ABI &lt; 0.9

          5. Patients with signed informed consent

        Exclusion Criteria:

          1. Acute critical limb ischemia

          2. Severe critical limb ischemia (Rutherford category 6)

          3. Known hypersensitivity or contraindication to any of the following medications:
             heparin, aspirin, clopidogrel, cilostazol, or contrast agents

          4. In-stent restenosis lesions (Restenosis lesions without previously implanted stents
             are eligible to the enrollment)

          5. Bypass graft lesions

          6. Age &gt; 85 years

          7. Severe hepatic dysfunction (&gt; 3 times normal reference values)

          8. Significant leucopenia, neutropenia, thrombocytopenia, anemia, or known bleeding
             diathesis

          9. LVEF &lt; 40% or clinically overt congestive heart failure

         10. Pregnant women or women with potential childbearing

         11. Life expectancy &lt;1 year due to comorbidity

         12. Untreated proximal inflow disease of the ipsilateral iliac arteries (more than 50%
             stenosis or occlusion)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Guk Ko, MD</last_name>
      <phone>82-2-2228-8460</phone>
      <email>ygko@yuhs.ac</email>
    </contact>
    <contact_backup>
      <last_name>Hyuck-Moon Kwon, MD, Ph.D</last_name>
      <phone>82-2-2019-3310</phone>
      <email>kwonhm@yuhs.ac</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 29, 2016</study_first_submitted>
  <study_first_submitted_qc>March 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2016</study_first_posted>
  <last_update_submitted>March 7, 2016</last_update_submitted>
  <last_update_submitted_qc>March 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral Artery Disease</keyword>
  <keyword>Femoropopliteal Artery</keyword>
  <keyword>Nitinol Stent</keyword>
  <keyword>Restenosis</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

